慢性乙型肝炎和慢性丙型肝炎抗病毒治疗疗效评价指标  

Antiviral efficacy evaluation indicators for patients with chronic hepatitis B and chronic hepatitis C

作　　者：喻苧 樊蓉[1] YU Ning;FAN Rong(Department of Hepatology Unit and Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院肝病中心暨感染内科,广东广州510515

出　　处：《中国实用内科杂志》2023年第5期369-374,共6页Chinese Journal of Practical Internal Medicine

摘　　要：慢性乙型肝炎(chronic hepatitis B,CHB)和慢性丙型肝炎(chronic hepatitis C,CHC)是威胁我国人民健康的重要公共卫生问题,是肝硬化和肝细胞癌(hepatocellular carcinoma,HCC)发生的主要危险因素。抗病毒治疗能够显著延缓疾病进展,降低CHB、CHC相关肝硬化失代偿和肝细胞癌风险,改善远期预后。在抗病毒治疗过程中,利用传统或新型的指标及其模型,可有效地监测抗病毒治疗疗效和疾病进展,可作为指导病毒性肝炎精准诊疗的重要工具。基于生物学标志物指导的诊疗策略有望进一步提升我国病毒性肝炎患者的治疗疗效,降低相关病死率,助力实现世界卫生组织提出的“2030年病毒性肝炎相关病死率下降65%”的宏伟目标。Chronic hepatitis B(CHB)and chronic hepatitis C(CHC)are major public health problems threatening the health of the people in China,and the main risk factors for liver cirrhosis and hepatocellular carcinoma(HCC).Antiviral therapy can significantly delay the disease progression,reduce the risk of decompensation cirrhosis OR HCC associated with CHB/CHC,and improve the long-term prognosis.During antiviral treatment,the traditional or novel indicators or their models can effectively monitor the efficacy of antiviral treatment and disease progression,which can be used as an important tool to guide the accurate diagnosis and treatment of viral hepatitis.The diagnosis and treatment strategies based on biomarkers are expected to further improve the treatment efficacy in patients with viral hepatitis in China,reduce the related mortality,and help achieve the ambitious goal of"reducing the viral hepatitis-related mortality by 65%by 2030"proposed by the World Health Organization.

关 键 词：慢性乙型肝炎 慢性丙型肝炎 抗病毒治疗 疗效评价 

分 类 号：R512.6[医药卫生—内科学]